Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05833594

Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma

Sponsor: Anhui Provincial Hospital

View on ClinicalTrials.gov

Summary

Chemoradiotherapy has been a standard modality for inoperable locally advance esophageal carcinoma. The goal of this randomized control study is to compare the feasibility, and survival benefits of whole-course immunonutrition combined with chemoradiotherapy±ICIs for local advanced patients with inoperable esophageal squamous cell carcinoma. The main questions it aims to answer are: • If the feasibility and safety of whole-course immunonutrition combined with chemoradiotherapy±ICIs is better. • If the survival benefits (1, 2 and 3-years progression free survival) of whole-course immunonutrition combined with chemoradiotherapy±ICIs is longer. The Experimental group will receive a combination immunonutrition of omega-3 fatty acids, and glutamine, whereas the control group will receive standard formula.

Official title: Anhui Provincial Hospita

Key Details

Gender

All

Age Range

18 Years - 85 Years

Study Type

OBSERVATIONAL

Enrollment

70

Start Date

2023-07-01

Completion Date

2026-12-01

Last Updated

2023-12-26

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs

The Experimental group received a combination of omega-3 fatty acids, and glutamine, whereas the control group received standard formula.

Locations (1)

Anhui provincial hospital

Hefei, China